8 completed, 2 terminated. 10 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 8, Terminated 2 |
| Phase 2 | 8 | Completed 6, Terminated 2 |
Follow Colorectal Tumors: new trials by email Literature Review of Colorectal Tumors trials Research Report on Colorectal Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation JDQ443, trametinib, Ribociclib - KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 74 | 2022-10-24 | 2026-10-21 |
| A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment NUC-3373 + leucovorin, NUC-3373, NUFOX - Colorectal Cancer, Colorectal Neoplasms | Phase 1 / Phase 2 | Completed | NuCana plc | 111 | 2018-10-05 | 2025-04-23 |
| An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread Nivolumab, Trametinib, Ipilimumab - Colorectal Cancer, Colorectal Tumors | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 325 | 2018-01-31 | 2025-12-03 |
| Safety of Labeled Dendritic Cell (DC) Vaccines and Feasibility of Tracking by Magnetic Resonance Imaging (MRI) DC Vaccine - Colorectal Neoplasms, Colorectal Cancer | Phase 1 | Completed | Pawel Kalinski | 6 | 2013-01-01 | 2017-09-26 |
| Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer Chemokin Modulatory Regimen (5 MU/m2), Chemokin Modulatory Regimen (10 MU/m2), Chemokin Modulatory Regimen (20 MU/m2) - Colorectal Cancer, Colorectal Carcinoma | Phase 1 / Phase 2 | Terminated | Roswell Park Cancer Institute | 15 | 2012-10-01 | 2023-10-27 |
| ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer ISIS 183750, Irinotecan - Colorectal Neoplasms, Colorectal Carcinoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 24 | 2012-08-01 | 2016-04-25 |
| Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer Panitumumab, Irinotecan, Everolimus - Colorectal Cancer, Colorectal Carcinoma | Phase 1 / Phase 2 | Completed | The Queen Elizabeth Hospital | 49 | 2010-06-01 | 2017-11-06 |
| Dendritic Cell Vaccination for Patients with Solid Tumors autologous dendritic cell vaccination - Glioblastoma, Renal Cell Carcinoma | Phase 1 / Phase 2 | Completed | University Hospital, Antwerp | 48 | 2010-05-03 | 2024-12-09 |
| Nelfinavir, a Phase I/Phase II Rectal Cancer Study nelfinavir - Colorectal Cancer, Colorectal Carcinoma | Phase 1 / Phase 2 | Completed | Maastricht Radiation Oncology | 15 | 2008-09-01 | 2014-12-08 |
| A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer RAD001, Cetuximab, Irinotecan - Colorectal Cancer, Colorectal Carcinoma | Phase 1 | Completed | Novartis Pharmaceuticals | 19 | 2007-05-01 | 2012-11-02 |
Colorectal Neoplasms (10) · Breast Neoplasms (1) · Carcinoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Glioblastoma (1) · Mesothelioma, Malignant (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Recurrence (1) · Sarcoma (1)
Colonic Diseases (10) · Digestive System Diseases (10) · Digestive System Neoplasms (10) · Gastrointestinal Diseases (10) · Gastrointestinal Neoplasms (10) · Intestinal Diseases (10) · Intestinal Neoplasms (10) · Neoplasms by Site (10) · Rectal Diseases (10) · Neoplasms (9) · Lung Diseases (2) · Lung Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2) · Respiratory Tract Diseases (2)
Irinotecan (4) · Cetuximab (3) · Everolimus (2) · Panitumumab (2) · trametinib (2) · Bevacizumab (1) · Celecoxib (1) · Interferon alpha-2 (1) · Interferon-alpha (1) · Introns (1) · Ipilimumab (1) · JDQ443 (1) · LY 2275796 (1) · Leucovorin (1) · Levoleucovorin (1)
Novartis Pharmaceuticals (2) · Bristol-Myers Squibb (1) · Maastricht Radiation Oncology (1) · National Cancer Institute (NCI) (1) · NuCana plc (1) · Pawel Kalinski (1) · Roswell Park Cancer Institute (1) · The Queen Elizabeth Hospital (1) · University Hospital, Antwerp (1)
United States (7) · Belgium (3) · Australia (2) · France (2) · Germany (2) · Italy (2) · Spain (2) · Argentina (1) · Canada (1) · Chile (1) · Czechia (1) · Netherlands (1) · Singapore (1) · South Korea (1) · United Kingdom (1)
Amanda Townsend, MBBS (1) · Amer H Zureikat, MD (1) · David L. Bartlett, MD (1) · Elisabeth Oelmann, MD PhD (1) · Ph. Lambin, MD PhD (1) · Tim F Greten, M.D. (1)
2017 (2), 2023 (1), R01CA134633 (1)